Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of ($0.03), $0.02 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $53.54 million versus the consensus estimate of $54.89 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.